Daclatasvir TRIO regimen has good cure rates for hepatitis C patients with or without cirrhosis
Young drug injectors on opioid maintenance therapy have lower risk of hepatitis C infection
Misunderstanding of questions regarding anal sex in microbicide HIV prevention trial
Once-daily dolutegravir superior to darunavir/ritonavir in 96-week follow-up
Doravirine works as well as efavirenz with fewer CNS side-effects
Sustained virological response to hepatitis C treatment reduces mortality, liver cancer and liver transplants
Sofosbuvir/ledipasvir cures nearly all genotype 1 HCV for people with HIV co-infection
Protease inhibitor monotherapy: darunavir/ritonavir less effective than three-drug therapy
Truvada PrEP use rising in United States, especially among men
